Why in news?
In 2026 Africa witnessed outbreaks of Marburg virus disease and researchers commenced trials for an experimental vaccine. The disease, which has a high fatality rate and no approved treatment, requires global vigilance to prevent further spread.
Background
Marburg virus disease (MVD) is a rare but severe haemorrhagic fever caused by two viruses from the Filoviridae family: Marburg virus and Ravn virus. The disease was first identified in 1967 when lab workers in Marburg, Germany, became ill after handling African green monkeys imported from Uganda. The natural reservoir is thought to be the Egyptian rousette bat.
Transmission and symptoms
- Spread: MVD does not spread through the air. Infection occurs through direct contact with blood or bodily fluids of an infected person or animal or via contaminated surfaces.
- Incubation and contagion: After exposure the incubation period ranges from two to twenty‑one days. Individuals are not contagious until they develop symptoms.
- Symptoms: Initial signs include sudden fever, chills, headache and muscle pain. Within a few days patients develop diarrhoea, abdominal pain and vomiting. Many also exhibit a rash and bleeding from gums, nose or injection sites. Severe cases progress to organ failure and shock.
- Fatality rate: Case fatality can range from 24 to 88 percent depending on the outbreak. The 2004‑05 Angola outbreak killed 227 of 252 patients. There is no approved vaccine or antiviral therapy yet.
Recent developments
- Outbreaks: In early 2026 Ethiopia confirmed multiple cases of MVD. Ghana and Equatorial Guinea also reported outbreaks in recent years. Swift isolation, contact tracing and safe burial practices helped contain these events.
- Vaccine research: In April 2026 the International AIDS Vaccine Initiative and partners began a Phase I trial of a single‑dose candidate called rVSV∆G‑MARV‑GP. The trial involves over a hundred volunteers and aims to assess safety and immune response.
- Preparedness: Health authorities urge travellers to avoid caves and mines inhabited by bats and to practise infection‑control measures when caring for patients.
Conclusion
Marburg virus disease remains a public health threat because of its high mortality and lack of specific treatment. Strengthening surveillance, rapid diagnostics and infection control are vital to prevent future outbreaks. Ongoing vaccine trials offer hope but until a licensed vaccine is available, supportive care and early containment will remain the mainstays of response.